Effects of Antipsychotic Administration on Brain Glutamate in Schizophrenia: A Systematic Review of Longitudinal (1)H-MRS Studies

Frontiers in Psychiatry
Alice EgertonPhilip K McGuire

Abstract

Schizophrenia is associated with brain glutamate dysfunction, but it is currently unclear whether antipsychotic administration can reduce the extent of glutamatergic abnormality. We conducted a systematic review of proton magnetic resonance spectroscopy ((1)H-MRS) studies examining the effects of antipsychotic treatment on brain glutamate levels in schizophrenia. The Medline database was searched to identify relevant articles published until December 2016. Inclusion required that studies examined longitudinal changes in brain glutamate metabolites in patients with schizophrenia before and after initiation of first antipsychotic treatment or a switch in antipsychotic treatment. The searches identified eight eligible articles, with baseline and follow-up measures in a total of 168 patients. The majority of articles reported a numerical reduction in brain glutamate metabolites with antipsychotic treatment, and the estimated overall mean reduction of 6.5% in Glx (the combined signal from glutamate and glutamine) across brain regions. Significant reductions in glutamate metabolites in at least one brain region were reported in four of the eight studies, and none of the studies reported a significant glutamatergic increase after anti...Continue Reading

References

Dec 20, 2003·Annals of the New York Academy of Sciences·Marc LaruelleAnissa Abi-Dargham
Sep 1, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Juan BustilloMatthew P Galloway
Jan 30, 2007·Journal of Psychopharmacology·James M StoneLyn S Pilowsky
Mar 16, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Xavier López-GilAlbert Adell
Oct 2, 2007·The British Journal of Psychiatry : the Journal of Mental Science·Jean ThébergePeter C Williamson
Jun 23, 2009·Pharmacology & Therapeutics·Raffaella MolteniMarco Andrea Riva
Jul 4, 2009·Psychopharmacology·Satoshi YamamuraMotohiro Okada
Jul 28, 2009·Journal of Clinical Epidemiology·David MoherUNKNOWN PRISMA Group
Aug 29, 2009·Journal of Proteome Research·Gerard A McLoughlinSabine Bahn
Nov 18, 2009·Molecular Psychiatry·J R BustilloJ Lauriello
Apr 22, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Camilo de la Fuente-SandovalAriel Graff-Guerrero
Jun 2, 2011·The British Journal of Psychiatry : the Journal of Mental Science·Naoko AoyamaPeter C Williamson
Jul 6, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Alice EgertonJames M Stone
Jun 12, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Alice EgertonPhilip K McGuire
Jan 22, 2015·The International Journal of Neuropsychopharmacology·Meghan Elizabeth GoldsteinBruce R Russell
Feb 26, 2016·Translational Psychiatry·J M StevensonJ R Bishop

❮ Previous
Next ❯

Citations

Oct 12, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Christian Stefan LegindBirte Yding Glenthøj
Dec 5, 2017·Psychological Medicine·Gemma ModinosSteve C R Williams
Jan 11, 2020·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Robert A McCutcheonOliver D Howes
Nov 14, 2019·Journal of Toxicologic Pathology·Guillermo FernandezRichard Briscoe
Jan 9, 2019·Frontiers in Psychiatry·Caroline MadeiraRogerio Panizzutti
May 2, 2019·Frontiers in Pharmacology·Antonio VitaMassimo Gennarelli
Jan 6, 2021·Schizophrenia Bulletin·Grant McQueenAlice Egerton
Jan 6, 2021·The American Journal of Psychiatry·Nina V KraguljacCharles B Nemeroff
Oct 28, 2019·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Maria RogdakiOliver Howes
Jul 3, 2021·International Journal of Molecular Sciences·Ariel FrajermanBoris Chaumette

❮ Previous
Next ❯

Methods Mentioned

BETA
nuclear magnetic resonance

Software Mentioned

WebPlotDigitizer

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.